Elite Pharmaceuticals has experienced a notable increase in revenue driven by an expanded portfolio of controlled-release generic drugs, including recent launches like generic Percocet® and Vyvanse®. This growth reflects the company's strategic emphasis on complex formulations that face higher entry barriers, supporting improved operating margins despite pricing pressures. The company’s liquidity and capital structure remain robust with strong working capital and ongoing debt service compliance. Looking ahead, pipeline developments and commercialization of FDA-approved ANDAs will be key growth catalysts, tempered by regulatory uncertainties and competitive generic drug market dynamics.